Translational Development Acquisition Corp. Ordinary Shares (TDAC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Translational Development Acquisition Corp. Ordinary Shares (TDAC) has a cash flow conversion efficiency ratio of -0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.24 Million) by net assets ($173.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Translational Development Acquisition Co to measure how much of total assets are equity-financed.
Translational Development Acquisition Corp. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Translational Development Acquisition Corp. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Translational Development Acquisition Co earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Translational Development Acquisition Corp. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Translational Development Acquisition Corp. Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Delta Corp Limited
NSE:DELTACORP
|
0.064x |
|
Shenzhen Weiye Decoration Group Co Ltd
SHE:300621
|
-1.074x |
|
Triplepoint Venture Growth BDC Corp
NYSE:TPVG
|
-0.020x |
|
Karel Elektronik Sanayi ve Ticaret AS
IS:KAREL
|
0.171x |
|
Lithium Royalty Corp
TO:LIRC
|
-0.001x |
|
Intelligent Monitoring Group Ltd
AU:IMB
|
0.149x |
|
Central Industrial Corp
KLSE:8052
|
-0.211x |
|
Healius Ltd
AU:HLS
|
0.162x |
Annual Cash Flow Conversion Efficiency for Translational Development Acquisition Corp. Ordinary Shares (2022–2024)
The table below shows the annual cash flow conversion efficiency of Translational Development Acquisition Corp. Ordinary Shares from 2022 to 2024. For the full company profile with market capitalisation and key ratios, see Translational Development Acquisition Co stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $168.75 Million | $-851.45K | -0.005x | -1355.59% |
| 2023-12-31 | $-507.66K | $-204.00 | 0.000x | -99.99% |
| 2022-12-31 | $-22.11K | $-97.16K | 4.395x | -- |
About Translational Development Acquisition Corp. Ordinary Shares
Translational Development Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.